Apcer Life Sciences India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-07-2024
- Paid Up Capital ₹ 0.50 M
as on 26-07-2024
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 8.75%
(FY 2023)
- Profit -19.80%
(FY 2023)
- Ebitda 5.17%
(FY 2023)
- Net Worth 19.19%
(FY 2023)
- Total Assets 8.88%
(FY 2023)
About Apcer Life Sciences India
The Corporate was formerly known as Apcer Pharma India Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Tejus Ravindra, Ravindra Pasta, and Ravindra Menon serve as directors at the Company.
- CIN/LLPIN
U51397MH2009PLC190958
- Company No.
190958
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Santacruz West, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Apcer Life Sciences India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tejus Ravindra  | Director | 16-Jan-2019 | Current |
| Ravindra Pasta | Director | 16-Mar-2009 | Current |
| Ravindra Menon | Director | 16-Mar-2009 | Current |
Financial Performance and Corporate Structure Insights of Apcer Life Sciences India.
Apcer Life Sciences India Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.75% increase. The company also saw a substantial fall in profitability, with a 19.8% decrease in profit. The company's net worth Soared by an impressive increase of 19.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apcer Life Sciences India?
In 2023, Apcer Life Sciences India had a promoter holding of 100.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Metta Life Sciences Private LimitedActive 14 years 6 monthsRavindra Pasta and Ravindra Menon are mutual person
Apc Pharmaceuticals And Chemicals Private LimitedActive 29 years 11 monthsRavindra Pasta and Ravindra Menon are mutual person
Apc Nutrients Private LimitedActive 18 years 11 monthsTejus Ravindra, Ravindra Pasta and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Apcer Life Sciences India?
Unlock and access historical data on people associated with Apcer Life Sciences India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apcer Life Sciences India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apcer Life Sciences India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
